A method of attaining virologic suppression in a heavily treatment-experinced (HTE) individual infected with the HIV-1 virus involves administering to the individual a treatment regimen comprising the drug fostemsavir together with an optimized background therapy (OBT). This treatment regimen should maintain virologic suppression to a plasma HIV-1 RNA level of less than 200 copies (c)/mL for an extended period.